Effect of Nervus Cutaneous Femoris Lateralis-Blockade on Moderate Pain Responders After Total Hip Arthroplasty

Daniel Hägi-Pedersen60 enrolled

Overview

The patients will be included the 1. or 2. day after surgery. All THA patients will be screened. Those reporting VAS \> 40 during active 30 degrees hip flexion will be asked to participate. Included patients will receive 2xNCFL (singleshot) first placebo (8 ml saline) and then ropivacaine (8 ml ropivacaine 7,5mg/ml) or the other way around (randomized). There will be 45 minutes between the two blockades. The blockades will be ultrasound guided.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Pain, Postoperative Ropivacaine Therapeutic Use Arthroplasty, Replacement, Hip

Interventions

RopivacaineDRUG

Arm RP is receiving 8 ml of ropivacaine 7,5 mg/ml at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with placebo (saline 8ml). Arm PR is receiving 8 ml of placebo (saline) at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with ropivacaine 8 ml.

SalineDRUG

Eligibility

Sex: ALLMin age: 30 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * THA within 48 hours and VAS\>40 during active 30 degrees hip flexion despite conventional pain medication. * informed consent * ASA 1-3 * BMI 18-40 Exclusion Criteria: * Unable to communicate in danish * Allergic reactions toward drugs used * Abuse of alcohol/drugs * Unable to cooperate * Pregnant women

Outcomes

Primary Outcomes

Difference in VAS between NCFL and placebo during active 30 degrees hip flexion

Time frame: 45 min

Secondary Outcomes

Difference in mean VAS between the groups during active hip flexion

Time frame: 15, 30, 45, 60, 75, 90 min

Difference in mean VAS between the groups at rest